Xcel Wealth Management LLC Acquires 10,735 Shares of Abbott Laboratories $ABT

Xcel Wealth Management LLC grew its stake in Abbott Laboratories (NYSE:ABT) by 55.2% during the first quarter, HoldingsChannel.com reports. The firm owned 30,182 shares of the healthcare product maker’s stock after buying an additional 10,735 shares during the period. Xcel Wealth Management LLC’s holdings in Abbott Laboratories were worth $3,099,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories during the 4th quarter worth approximately $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, opening a potential new growth avenue in high-demand neurology testing. Article: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Recent commentary highlighted Abbott’s expanding diabetes franchise, especially FreeStyle Libre, and said the stock looks attractive after sector rotation pushed it lower, with one note calling it a “Buy” on growth and catalyst potential. Article: Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
• Positive Sentiment: Multiple articles pointed to strong investor sentiment, including bullish hedge fund positioning and estimates of roughly 31% upside, suggesting Wall Street still views Abbott as a quality large-cap healthcare name. Article: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Coverage also emphasized Abbott’s dividend record, four-segment business model, and recession-resistant cash flow, which can support the stock during periods of market rotation away from defensive names. Article: 3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
• Neutral Sentiment: Abbott said it will host its second-quarter earnings conference call on July 16, keeping attention on upcoming results and guidance but not changing fundamentals yet. Article: Abbott hosts conference call for second-quarter earnings
• Neutral Sentiment: Other recent pieces cited emerging-market momentum in established pharmaceuticals and new sensor distribution in Europe, adding to the bullish narrative without being major near-term stock drivers. Article: How Are Emerging Markets Supporting Abbott’s EPD Momentum?

Abbott Laboratories Stock Performance

Shares of ABT opened at $93.12 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.54. The firm’s 50 day moving average price is $89.23 and its two-hundred day moving average price is $105.46. The firm has a market cap of $162.19 billion, a P/E ratio of 26.08, a PEG ratio of 1.56 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the prior year, the firm earned $1.09 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Analysts Set New Price Targets

ABT has been the subject of several recent analyst reports. Evercore lowered their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Leerink Partners dropped their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Finally, Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a report on Wednesday, April 22nd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.